Phase 2 Study of Enzalutamide and GnRH Agonist Before, During and After Radiation Therapy in Treatment of Patients With High-risk Localized Prostate Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Enzalutamide (Primary) ; Leuprorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 06 Sep 2019 Planned End Date changed from 1 Apr 2019 to 1 Dec 2019.
- 06 Sep 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Dec 2019.
- 09 May 2018 Status changed from recruiting to active, no longer recruiting.